Drug companies want weight-loss drug money

More than 18 weight loss drugs are in development because drug companies know that the market is worth billions of dollars even though insurance companies are still debating their coverage for weight loss. It’s going to be a knockout, drag-down battle.

Bloomberg says, “at least $100 billion annually is potentially riding on new weight loss drugs. In the US alone, about 130 million adults are eligible for GLP-1s because of their weight and other health conditions. If just a third of Americans with severe obesity took them, US sales of weight loss drugs would swell more than 30 times, into an $80 billion industry, according to data analytics company Airfinity Ltd. Analysts at Jefferies Financial Group Inc. predict that GLP-1s for diabetes and obesity could become the biggest blockbusters of all time, bringing in as much as $150 billion a year globally.”

Private and public insurers aren’t convinced they’re worth covering. Medicare, the federal health insurance program for the elderly and some people on long-term disability, put weight loss in the same category as balding and erectile dysfunction. Three-quarters of private insurers don’t cover weight loss drugs, either. Most state Medicaid programs for low-income and disabled Americans restrict coverage, too, with just 10 offering broad coverage, according to a Bloomberg Businessweek survey of…